Other Pharmaceuticals - EAEU

EAEU

The Other Pharmaceuticals market in the EAEU is estimated to achieve a revenue of US$3.32bn by 2024.
This projection indicates a steady growth rate with a Compound Annual Growth Rate (CAGR 2024-2029) of 3.27%.
Consequently, the market volume is predicted to reach US$3.90bn by 2029.
When compared globally, United States is expected to generate the highest revenue in the Other Pharmaceuticals market, reaching a staggering US$260.50bn in 2024.
The EAEU market for other pharmaceuticals is experiencing a surge in demand due to the growing aging population and increased focus on healthcare.

Key regions: China, Europe, Australia, United States, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Pharmaceuticals market in EAEU has been experiencing significant growth in recent years.

Customer preferences: Customers in the EAEU region have been increasingly demanding more affordable and accessible healthcare options. This has led to a rise in demand for generic drugs, including Other Pharmaceuticals. Additionally, the aging population in the region has also contributed to the growth of the market.

Trends in the market: Russia has been the largest market for Other Pharmaceuticals in the EAEU region. The country has been experiencing a growth in the market due to the increasing demand for affordable healthcare options. Kazakhstan and Belarus have also been significant markets for Other Pharmaceuticals in the region. The growth in these countries has been driven by the rising demand for generic drugs.

Local special circumstances: The EAEU region has a complex regulatory environment, which can create challenges for companies looking to enter the market. Companies must navigate different regulatory requirements in each country, which can be time-consuming and costly. Additionally, the region has a diverse population with different healthcare needs and preferences, which can make it difficult for companies to develop products that meet the needs of all consumers.

Underlying macroeconomic factors: The growth of the Other Pharmaceuticals market in the EAEU region is largely driven by the underlying macroeconomic factors in the region. The region has been experiencing economic growth in recent years, which has led to an increase in disposable income and a rise in demand for healthcare products. Additionally, the region has a large population, which provides a significant market opportunity for companies operating in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.